Stock ALCLS CELLECTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris
Other stock markets
 11:35:19 2024-04-29 am EDT 		5-day change 1st Jan Change
2.45 EUR +4.48% Intraday chart for Cellectis S.A. -0.20% -11.36%
Apr. 26 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cellectis S A : publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023
Cellectis S A : Rapport financier 2023
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
C'est grave, docteur Powell ?
En Direct des Marchés : Publicis, Airbus, Société Générale, Vertex, Givaudan, UBS, KKR, Catana...
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
On s'occupe comme on peut
En Direct des Marchés : EsssilorLuxottica, Bouygues, Atos, BioMérieux, UBS, Eli Lilly, L'Occitane...
Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALCLS Stock
  4. News Cellectis S.A.
  5. Other languages